Emergence of EPR effect theory and development of clinical applications for cancer therapy

Therapeutic Delivery

Volumn 5, Issue 6, 2014, Pages 627-630

  Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRADYKININ; ZINOSTATIN;

ARTICLE; BIOLOGY; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CANCER THERAPY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG SYNTHESIS; DRUG UPTAKE; ENHANCED PERMEABILITY AND EFFECT; HUMAN; IN VIVO STUDY; INFECTION; INFLAMMATION; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOLECULAR WEIGHT; NANOMEDICINE; PHARMACOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SOLID TUMOR; STREPTOMYCES; STREPTOMYCES CARZINOSTATICUS; THEORY; CAPILLARY PERMEABILITY; NEOPLASM; PERMEABILITY; PHOTOCHEMOTHERAPY;

CAPILLARY PERMEABILITY; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NEOPLASMS; PERMEABILITY; PHOTOCHEMOTHERAPY;

EID: 84905487433     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.36     Document Type: Article

References (20)

1. Maeda H, Konno T. Metamorphosis of neocarzinostatin to SMANCS: chemistry, biology, pharmacology, and clinical effect of the first prototype anticancer polymer therapeutic. In: Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug. Maeda H, Edo K, Ishida N (Eds). Springer-Verlag, Tokyo, Japan, 227-267 (1997).
2. Maeda H. Microbial proteinases and pathogenesis of infection. In: The Encyclopedia of Molecular Medicine (Volume 4). Creighton TE (Ed.). John Wiley & Sons, Inc., NY, USA, 2663-2668 (2002).
3. Oda T, Akaike T, Hamamoto T et al. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 244, 974-976 (1989).
4. Akaike T, Noguchi Y, Ijiri S et al. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl Acad. Sci. USA 93, 2448-2453 (1996).
5. Matsumura Y, Maruo K, Kimura M et al. Kinin-generating cascade in advanced cancer patients and in vitrostudy. Jpn. J. Cancer Res. 82, 732-741 (1991).
6. Maeda H. The link between infection and cancer. Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci. 104, 779-789 (2013).
7. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6, 181-202 (1991).
8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46, 6387-6392 (1986).
9. Maeda H, Takeshita J,Yamashita A. Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. Eur. J. Cancer 16, 723-731 (1980).
10. Maeda H, Takeshita J, Kanamaru R et al. Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent-and water-soluble polymer-conjugated protein. Gann 70, 601-606 (1979).
11. Maeda H,Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6, 193-210 (1989).
12. Daruwalla J, Nikfarjam M, Greish K et al. In vitro and in vivo evaluation of tumor targeting SMA-pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci. 101, 1866-1874 (2010).
13. Ohtsuka N, Konno T, Miyauchi Y et al. Anticancer effects of arterial administration of the anticancer agent SMANCS with Lipiodol on metastatic lymph nodes. Cancer 59, 1560-1565 (1987).
14. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and x-ray image. Cancer Res. 44, 2115-2121 (1984).
15. Konno T, Maeda H, Iwai K et al. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54, 2367-2374 (1984).
16. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS:cases of advanced solid tumors. Jpn. J. Clin.Oncol. 39, 756-766 (2009).
17. Oka K, Miyamoto Y,Matsumura Y et al. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation. Pharmaceut. Res. 7, 852-855 (1990).
18. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 164, 138-144 (2012).
19. Yasuda H, Yamaya M, Nakayama K et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol. 24, 688-694 (2006).
20. Gomer CJ, Ferrario A. Tissue distribution and photosensitizing properties of mono-l-aspartylchlorin e6 in a mouse tumor model.. Cancer Res. 50, 3985-3990 (1990).